ANVISA authorized regulations that are new the roll-out of medicinal services and products produced from cannabis
The Brazilian Health Regulatory Agency (ANVISA) authorized, at the start of December 2019, laws that enable the purchase in pharmacies of cannabis-based services and products for medical purposes. The procedures for manufacturing and importing such products and the requirements for prescription, sale, and supervision are approved in these new proposals. Authorization doesn’t add substance managing in pharmacies and it is just permitted to offer – by prescription – items currently developed straight through the maker. The authorized guidelines will continue to be in force for 36 months, and after that a unique standard are granted, thinking about the outcomes acquired with this initial duration.
This choice is just a progress to your health sector that is brazilian. We’re seeing a global trend of this rediscovery of Cannabis sativa properties beyond its leisure traits, consequently probably one of the most appropriate talks through the perspective of the latest medications today may be the substances produced from cannabis, called cannabinoids. The substances removed through the plant currently contain much more than 100 cataloged active substances that act on endocannabinoid receptors and are also effective in a variety of circumstances as medications or as accessory substances, increasing or eliminating negative effects or improving the outcome of treatment.